Back to search

Peptide record

TPDB16434

ZXR-2 Antibacterial Anticancer standard
16 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB16434
ZXR-2
Antibacterial Anticancer
Anti-infective peptides Cancer-related peptides
dbAMP CancerPPD 2.0
standard
No
A 16-aa standard natural multi-activity (Antibacterial and Anticancer) peptide sequence curated from dbAMP and CancerPPD 2.0, with an available 3D structural model.
Sequence
FKIGGFIKKLWRSLLA
Physicochemical Analysis
C93H149N23O18
NDCEQHMPTYV
LK
1877.35
11.73
4
0
9
+4
-2.65
0.569
128.12
Mammalian: 1.1 hour Yeast: 3 min E.coli: 2 min
5500
292.97
1
Residue Composition
number
1
A
1
R
0
N
0
D
0
C
0
E
0
Q
2
G
0
H
2
I
3
L
3
K
0
M
2
F
0
P
1
S
0
T
1
W
0
Y
0
V
Amino Acid Distribution
A: 1 R: 1 N: 0 D: 0 C: 0 E: 0 Q: 0 G: 2 H: 0 I: 2 L: 3 K: 3 M: 0 F: 2 P: 0 S: 1 T: 0 W: 1 Y: 0 V: 0
Chemical Descriptors
16
C93H149N23O18
1877.35
11.73
+4
-2.65
0.569
Free
L
Linear
Free
Antimicrobial
Synthetic Mutant form of ZXR-I
Evidence Records 7 records
Evidence 1 Activity

Activity

IC50
IC50 = 8.1 ± 1.6 µM
Anticancer
8.1

Target

Cervical Cancer
HeLa
Cervix

Assay & Model

MTT assay
4-h

Source & Reference

CancerPPD 2.0
CancerPPD2
2016

Other

Source Activity Label Source Definition
Anticancer
CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation.
Evidence 2 Activity

Activity

IC50
IC50 = 9.9 ± 1.7 µM
Anticancer
9.9

Target

Salivary Cancer
SACC-83
Salivary gland

Assay & Model

MTT assay
4-h

Source & Reference

CancerPPD 2.0
CancerPPD2
2016
Evidence 3 Activity

Activity

IC50
IC50 = 7.5 ± 1.2 µM
Anticancer
7.5

Target

Liver Cancer
HepG-2
Liver

Assay & Model

MTT assay
4-h

Source & Reference

CancerPPD 2.0
CancerPPD2
2016
Evidence 4 Activity

Activity

IC50
IC50 = 8.4 ± 1.1 µM
Anticancer
8.4

Target

Liver Cancer
Huh-7
Liver

Assay & Model

MTT assay
4-h

Source & Reference

CancerPPD 2.0
CancerPPD2
2016
Evidence 5 Activity

Activity

IC50
IC50 = 14.2 ± 0.5 µM
Anticancer
14.2

Target

Prostate Cancer
PC-3
Prostate

Assay & Model

MTT assay
4-h

Source & Reference

CancerPPD 2.0
CancerPPD2
2016
Evidence 6 Activity

Activity

IC50
IC50 = 6.3 ± 0.7 µM
Anticancer
6.3

Target

Kidney Cancer
293T
Kidney

Assay & Model

MTT assay
4-h

Source & Reference

CancerPPD 2.0
CancerPPD2
2016
Evidence 7 Activity

Activity

40% LDH release at 32 µM
Anticancer

Target

Cervical Cancer
HeLa
Cervix

Assay & Model

LDH leakage assay
2-h

Source & Reference

CancerPPD 2.0
CancerPPD2
2017